US64131A1051 - Common Stock
NASDAQ:STIM (1/30/2023, 7:23:04 PM)+0.04 (+0.69%)
GICS Sector | Health Care | ||
GICS Industry | Health Care Equipment & Supplies |
Valuation | Growth | ||
Profitability | Health | ||
Dividend |
Earnings (Last) | 11-08 2022-11-08/bmo | Earnings (Next) | 03-06 2023-03-06 |
Ins Owners | 8.37% | Inst Owners | 63.6% |
Market Cap | 158.97M | Shares | 27.22M |
PE | N/A | Fwd PE | N/A |
Dividend Yield | N/A | Analysts | 82 |
IPO | 06-28 2018-06-28 |
Find more stocks on Nasdaq
Find more stocks on the USA
Find competitors from the same sector on the USA
Find competitors from the same industry on the USA
Find stocks with similar TA and Setup ratings on the USA
Find stocks with similar Fundamental rating on the USA
Find the competitors with the best technical ratings on the USA
Find the competitors with the best technical and setup ratings on the USA
Find the competitors with the best fundamentals on the USA
Find the competitors with the best valuation on the USA
Find the competitors with the best dividend on the USA
Find the competitors with the best analyst ratings on the USA
Neuronetics, Inc. commercial stage medical technology company, which engages in the designing, developing and marketing products for the patients suffering from psychiatric disorders. The company is headquartered in Malvern, Pennsylvania and currently employs 198 full-time employees. The company went IPO on 2018-06-28. The firm is focused on designing, developing, and marketing products for patients who suffer from neurohealth disorders. Its commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation (TMS) to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The NeuroStar Advanced Therapy System is used to treat adult patients with major depressive disorder (MDD). The firm intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications. The firm sells its NeuroStar Advanced Therapy System and recurring treatment sessions in the United States. Its primary focus is on selling to psychiatrists, with primary care physicians and pain management specialists.
NEURONETICS INC
31 General Warren Blvd.
Malvern PENNSYLVANIA 19355
P: 16106404202.0
CEO: Keith J. Sullivan
Employees: 198
Website: https://neurostar.com/neuronetics/
Neuronetics, Inc. (STIM) and Canada-based mental care provider Greenbrook TMS (GBNH) announced a six-year deal on Thursday for TMS devices. Read the full story here.
MALVERN, Pa. and TORONTO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on...
MALVERN, Pa., Jan. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety
Peer-reviewed publication shows NeuroStar TMS as an effective non-drug treatment for depression with comorbid anxiety...
MALVERN, Pa., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing,...
Here you can normally see the latest stock twits on STIM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: